[Multiple myeloma]

Rinsho Ketsueki. 2012 Feb;53(2):155-63.
[Article in Japanese]
No abstract available

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Boronic Acids / administration & dosage
  • Boronic Acids / adverse effects
  • Bortezomib
  • Denosumab
  • Diphosphonates / administration & dosage
  • Humans
  • Imidazoles / administration & dosage
  • Melphalan / administration & dosage
  • Multiple Myeloma / drug therapy*
  • Peripheral Nervous System Diseases / chemically induced
  • Peripheral Nervous System Diseases / prevention & control
  • Prednisolone / administration & dosage
  • Pyrazines / administration & dosage
  • Pyrazines / adverse effects
  • Randomized Controlled Trials as Topic
  • Thalidomide / administration & dosage
  • Thalidomide / adverse effects
  • Thalidomide / analogs & derivatives
  • Thalidomide / therapeutic use
  • Zoledronic Acid

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Boronic Acids
  • Diphosphonates
  • Imidazoles
  • Pyrazines
  • Denosumab
  • Thalidomide
  • Bortezomib
  • Zoledronic Acid
  • Prednisolone
  • pomalidomide
  • Melphalan